keyword
MENU ▼
Read by QxMD icon Read
search

DL4

keyword
https://www.readbyqxmd.com/read/27911371/development-of-stem-cell-derived-antigen-specific-regulatory-t-cells-against-autoimmunity
#1
Mohammad Haque, Kristin Fino, Praneet Sandhu, Jianxun Song
Autoimmune diseases arise due to the loss of immunological self-tolerance. Regulatory T cells (Tregs) are important mediators of immunologic self-tolerance. Tregs represent about 5 - 10% of the mature CD4(+) T cell subpopulation in mice and humans, with about 1 - 2% of those Tregs circulating in the peripheral blood. Induced pluripotent stem cells (iPSCs) can be differentiated into functional Tregs, which have a potential to be used for cell-based therapies of autoimmune diseases. Here, we present a method to develop antigen (Ag)-specific Tregs from iPSCs (i...
November 8, 2016: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/27475674/a-phase-1-study-of-stereotactic-body-radiation-therapy-dose-escalation-for-borderline-resectable-pancreatic-cancer-after-modified-folfirinox-nct01446458
#2
Walid L Shaib, Natalyn Hawk, Richard J Cassidy, Zhengjia Chen, Chao Zhang, Edith Brutcher, David Kooby, Shishir K Maithel, Juan M Sarmiento, Jerome Landry, Bassel F El-Rayes
PURPOSE: A challenge in borderline resectable pancreatic cancer (BRPC) management is the high rate of positive posterior margins (PM). Stereotactic body radiation therapy (SBRT) allows for higher radiation delivery dose with conformity. This study evaluated the maximal tolerated dose with a dose escalation plan level up to 45 Gy using SBRT in BRPC. METHODS AND MATERIALS: A single-institution, 3 + 3 phase 1 clinical trial design was used to evaluate 4 dose levels of SBRT delivered in 3 fractions to the planning target volume (PTV) with a simultaneous in-field boost (SIB) to the PM...
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27166161/golgi-analysis-of-neuron-morphology-in-the-presumptive-somatosensory-cortex-and-visual-cortex-of-the-florida-manatee-trichechus-manatus-latirostris
#3
Laura D Reyes, Tessa Harland, Roger L Reep, Chet C Sherwood, Bob Jacobs
The current study investigates neuron morphology in presumptive primary somatosensory (S1) and primary visual (V1) cortices of the Florida manatee (Trichechus manatus latirostris) as revealed by Golgi impregnation. Sirenians, including manatees, have an aquatic lifestyle, a large body size, and a relatively large lissencephalic brain. The present study examines neuron morphology in 3 cortical areas: in S1, dorsolateral cortex area 1 (DL1) and cluster cortex area 2 (CL2) and in V1, dorsolateral cortex area 4 (DL4)...
2016: Brain, Behavior and Evolution
https://www.readbyqxmd.com/read/25976292/a-phase-1-dosing-study-of-ruxolitinib-in-children-with-relapsed-or-refractory-solid-tumors-leukemias-or-myeloproliferative-neoplasms-a-children-s-oncology-group-phase-1-consortium-study-advl1011
#4
Mignon L Loh, Sarah K Tasian, Karen R Rabin, Patrick Brown, Daniel Magoon, Joel M Reid, Xuejun Chen, Charlotte H Ahern, Brenda J Weigel, Susan M Blaney
BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations. PROCEDURE: A phase 1 trial of ruxolitinib was performed to determine the maximum tolerated or recommended phase 2 dose, dose-limiting toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) in children with recurrent/refractory solid tumors (STs). Ruxolitinib was administered twice daily (BID) in 28-day cycles at five dose levels (15, 21, 29, 39, and 50 mg/m(2)/dose)...
October 2015: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/25311507/specific-fibroblastic-niches-in-secondary-lymphoid-organs-orchestrate-distinct-notch-regulated-immune-responses
#5
Nicolas Fasnacht, Hsin-Ying Huang, Ute Koch, Stéphanie Favre, Floriane Auderset, Qian Chai, Lucas Onder, Sandra Kallert, Daniel D Pinschewer, H Robson MacDonald, Fabienne Tacchini-Cottier, Burkhard Ludewig, Sanjiv A Luther, Freddy Radtke
Fibroblast-like cells of secondary lymphoid organs (SLO) are important for tissue architecture. In addition, they regulate lymphocyte compartmentalization through the secretion of chemokines, and participate in the orchestration of appropriate cell-cell interactions required for adaptive immunity. Here, we provide data demonstrating the functional importance of SLO fibroblasts during Notch-mediated lineage specification and immune response. Genetic ablation of the Notch ligand Delta-like (DL)1 identified splenic fibroblasts rather than hematopoietic or endothelial cells as niche cells, allowing Notch 2-driven differentiation of marginal zone B cells and of Esam(+) dendritic cells...
October 20, 2014: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/24885571/a-variant-of-green-fluorescent-protein-exclusively-deposited-to-active-intracellular-inclusion-bodies
#6
Govindan Raghunathan, Ganapathiraman Munussami, Hyojin Moon, Hyun-jong Paik, Seong Soo A An, Yong-Sung Kim, Sebyung Kang, Sun-Gu Lee
BACKGROUND: Inclusion bodies (IBs) were generally considered to be inactive protein deposits and did not hold any attractive values in biotechnological applications. Recently, some IBs of recombinant proteins were confirmed to show their functional properties such as enzyme activities, fluorescence, etc. Such biologically active IBs are not commonly formed, but they have great potentials in the fields of biocatalysis, material science and nanotechnology. RESULTS: In this study, we characterized the IBs of DL4, a deletion variant of green fluorescent protein which forms active intracellular aggregates...
2014: Microbial Cell Factories
https://www.readbyqxmd.com/read/24496920/phase-i-study-of-weekly-nab-paclitaxel-weekly-cetuximab-intensity-modulated-radiation-therapy-imrt-in-patients-with-stage-iii-ivb-head-and-neck-squamous-cell-carcinoma-hnscc
#7
M G Fury, E J Sherman, S S Rao, S Wolden, S Smith-Marrone, B Mueller, K K Ng, P R Dutta, D Y Gelblum, J L Lee, R Shen, S Kurz, N Katabi, S Haque, N Y Lee, D G Pfister
BACKGROUND: There is a clinical need to improve the efficacy of standard cetuximab + concurrent intensity-modulated radiation therapy (IMRT) for patients with locally and/or regionally advanced HNSCC. Taxanes have radiosensitizing activity against HNSCC, and nab-paclitaxel may offer therapeutic advantage in comparison with other taxanes. PATIENTS AND METHODS: This was a single-institution phase I study with a modified 3 + 3 design. Four dose levels (DLs) of weekly nab-paclitaxel were explored (30, 45, 60, and 80 mg/m(2)), given with standard weekly cetuximab (450 mg/m(2) loading dose followed by 250 mg/m(2) weekly) and concurrent IMRT (total dose, 70 Gy)...
March 2014: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/23988616/induction-of-t-cell-development-by-delta-like-4-expressing-fibroblasts
#8
Mahmood Mohtashami, Divya K Shah, Korosh Kianizad, Geneve Awong, Juan Carlos Zúñiga-Pflücker
The thymus provides a unique environment for the induction of T-cell lineage commitment and differentiation, which is predicted by specific Notch ligand-receptor interactions on epithelial cells and lymphoid progenitors, respectively. Accordingly, a bone marrow-derived stromal cell line (OP9) ectopically expressing the Notch ligand Delta-like 1 (Dll1) or Dll4 (OP9-DL1 and OP9-DL4, respectively) gains the ability to recapitulate thymus-like function, supporting T-cell differentiation of both mouse and human progenitors...
October 2013: International Immunology
https://www.readbyqxmd.com/read/23881845/dl4-mediated-notch-signaling-is-required-for-the-development-of-fetal-%C3%AE-%C3%AE-and-%C3%AE-%C3%AE-t-cells
#9
Isabel Ferrero, Ute Koch, Stephanie Claudinot, Stéphanie Favre, Freddy Radtke, Sanjiv A Luther, H R MacDonald
T-cell development depends upon interactions between thymocytes and thymic epithelial cells (TECs). The engagement of delta-like 4 (DL4) on TECs by Notch1 expressed by blood-borne BM-derived precursors is essential for T-cell commitment in the adult thymus. In contrast to the adult, the earliest T-cell progenitors in the embryo originate in the fetal liver and migrate to the nonvascularized fetal thymus via chemokine signals. Within the fetal thymus, some T-cell precursors undergo programmed TCRγ and TCRδ rearrangement and selection, giving rise to unique γδ T cells...
November 2013: European Journal of Immunology
https://www.readbyqxmd.com/read/23240034/deletional-protein-engineering-based-on-stable-fold
#10
Govindan Raghunathan, Nagasundarapandian Soundrarajan, Sriram Sokalingam, Hyungdon Yun, Sun-Gu Lee
Diversification of protein sequence-structure space is a major concern in protein engineering. Deletion mutagenesis can generate a protein sequence-structure space different from substitution mutagenesis mediated space, but it has not been widely used in protein engineering compared to substitution mutagenesis, because it causes a relatively huge range of structural perturbations of target proteins which often inactivates the proteins. In this study, we demonstrate that, using green fluorescent protein (GFP) as a model system, the drawback of the deletional protein engineering can be overcome by employing the protein structure with high stability...
2012: PloS One
https://www.readbyqxmd.com/read/23235319/phase-i-trial-of-gemcitabine-combined-with-capecitabine-and-erlotinib-in-advanced-pancreatic-cancer-a-clinical-and-pharmacological-study
#11
E Francois, J Bennouna, E Chamorey, M C Etienne-Grimaldi, N Renée, H Senellart, C Michel, P Follana, V Mari, J Y Douillard, G Milano
BACKGROUND: The aim of this phase I trial was to define the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose of erlotinib combined with capecitabine and gemcitabine in the treatment of advanced pancreatic cancer (APC). METHODS: Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day. Oral erlotinib was administered daily continuously at escalating doses (28-day cycle)...
2012: Chemotherapy
https://www.readbyqxmd.com/read/22240778/phase-i-study-of-lapatinib-plus-vinorelbine-in-patients-with-locally-advanced-or-metastatic-breast-cancer-overexpressing-her2
#12
MULTICENTER STUDY
E Brain, N Isambert, F Dalenc, V Diéras, J Bonneterre, K Rezai, M Jimenez, F Mefti-Lacheraf, E Cottura, P Tresca, L Vanlemmens, C Mahier-Aït Oukhatar, F Lokiec, P Fumoleau
BACKGROUND: To determine the recommended doses of lapatinib (LPT) combined with vinorelbine (VNR) in women with human epidermal growth factor receptor 2-overexpressing advanced breast cancer pretreated with trastuzumab. METHODS: In this phase I study, women were treated with oral daily LPT and i.v. VNR infused on days 1 and 8 every 3 weeks. Dose levels (DL) of LPT (mg)/VNR (mg m(-2)) ranged from 750/20 to 1250/30. The primary end point was feasibility based on maximal tolerated dose (MTD) and maximum administered dose (MAD)...
February 14, 2012: British Journal of Cancer
https://www.readbyqxmd.com/read/21931869/notch3-is-dispensable-for-thymocyte-%C3%AE-selection-and-notch1-induced-t-cell-leukemogenesis
#13
Sara Suliman, Joanne Tan, Keli Xu, Philaretos C Kousis, Paul E Kowalski, Greg Chang, Sean E Egan, Cynthia Guidos
Notch1 (N1) signaling induced by intrathymic Delta-like (DL) ligands is required for T cell lineage commitment as well as self-renewal during "β-selection" of TCRβ⁺CD4⁻CD8⁻ double negative 3 (DN3) T cell progenitors. However, over-expression of the N1 intracellular domain (ICN1) renders N1 activation ligand-independent and drives leukemic transformation during β-selection. DN3 progenitors also express Notch3 (N3) mRNA, and over-expression of ligand-independent mutant N3 (ICN3) influences β-selection and drives T cell leukemogenesis...
2011: PloS One
https://www.readbyqxmd.com/read/21750117/a-dose-escalation-study-of-gemcitabine-plus-oxaliplatin-in-combination-with-imatinib-for-gemcitabine-refractory-advanced-pancreatic-adenocarcinoma
#14
N Starling, E A Hawkes, I Chau, D Watkins, J Thomas, J Webb, G Brown, K Thomas, Y Barbachano, J Oates, D Cunningham
BACKGROUND: Targeting platelet-derived growth factor receptor-β (PDGFR-β) is a potential strategy to reduce tumour-related interstitial fluid pressure, enhance cytotoxic drug uptake and reduce chemoresistance. This study aimed to define safe doses of gemcitabine plus oxaliplatin when combined with imatinib (potent PDGFR-β inhibitor) in patients with advanced gemcitabine-refractory pancreatic cancer (PC). PATIENTS AND METHODS: Using a 3 + 3 dose escalation design, patients of performance status zero or one were entered into five sequential dose levels (DLs) of gemcitabine [day 1, from 400 (DL1) to 1000 mg/m(2) (DL4)] and oxaliplatin [day 2, 85 (DL1-4) and 100 mg/m(2) (DL5)] two weekly...
April 2012: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/21097675/lunatic-fringe-prolongs-delta-notch-induced-self-renewal-of-committed-%C3%AE-%C3%AE-t-cell-progenitors
#15
Julie S Yuan, Joanne B Tan, Ioana Visan, Irina R Matei, Peter Urbanellis, Keli Xu, Jayne S Danska, Sean E Egan, Cynthia J Guidos
Lunatic Fringe (Lfng) enhances Notch1 activation by Delta-like 4 (DL4) to promote Notch1-dependent T-lineage commitment of thymus-seeding progenitors. Subsequently, Notch1 and T-cell receptor-β (TCRβ)-containing pre-TCR complexes signal CD4/CD8 double-negative 3 (DN3) committed T-cell progenitors to survive, proliferate, and differentiate into CD4/CD8 double-positive (DP) αβ T-cell precursors. Few DP thymocytes develop without Notch1 or pre-TCR signals, whereas ectopic Notch1 activation causes T-cell leukemia...
January 27, 2011: Blood
https://www.readbyqxmd.com/read/20844195/lunatic-fringe-enhances-competition-for-delta-like-notch-ligands-but-does-not-overcome-defective-pre-tcr-signaling-during-thymocyte-beta-selection-in-vivo
#16
Ioana Visan, Julie S Yuan, Ying Liu, Pamela Stanley, Cynthia J Guidos
Notch1 activation by Delta-like (DL) Notch ligands is essential to induce T cell commitment and to suppress B cell development from thymus-seeding progenitors. Thymus-seeding progenitor competition for DL4 is critically regulated by Lunatic Fringe (Lfng), which glycosylates epidermal growth factor repeats in the Notch1 extracellular domain to enhance binding avidity for DL ligands. Notch1 activation is also essential for the process of β-selection, which drives TCRβ(+) CD4/CD8 double-negative 3 (DN3) precursors to proliferate and generate a large pool of CD4/CD8 double-positive thymocytes...
October 15, 2010: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/19858399/dose-finding-and-early-efficacy-study-of-gemcitabine-plus-capecitabine-in-combination-with-bevacizumab-plus-erlotinib-in-advanced-pancreatic-cancer
#17
Naureen Starling, David Watkins, David Cunningham, Janet Thomas, Janine Webb, Gina Brown, Karen Thomas, Jacqui Oates, Ian Chau
PURPOSE: This study evaluated safety and efficacy of chemotherapy (gemcitabine plus capecitabine) plus bevacizumab/erlotinib in advanced pancreatic cancer because dual epidermal growth factor receptor/vascular endothelial growth factor blockade has a rational biologic basis in this malignancy. PATIENTS AND METHODS: Patients with untreated, unresectable, locally advanced or metastatic pancreatic carcinoma were enrolled onto one of the following four sequential dose levels (DLs) of escalating capecitabine doses (days 1 to 21): DL1, 910 mg/m(2); DL2, 1,160 mg/m(2); DL3, 1,400 mg/m(2); or DL4, 1,660 mg/m(2)...
November 20, 2009: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/19050235/cutting-edge-thymic-crosstalk-regulates-delta-like-4-expression-on-cortical-epithelial-cells
#18
Emma Fiorini, Isabel Ferrero, Estelle Merck, Stéphanie Favre, Michel Pierres, Sanjiv A Luther, H Robson MacDonald
Interactions between Notch1 receptors on lymphoid progenitors and Delta-like 4 (DL4) ligands on cortical thymic epithelial cells (cTEC) are essential for T cell lineage commitment, expansion, and maturation in the thymus. Using a novel mAb against DL4, we show that DL4 levels on cTEC are very high in the fetal and neonatal thymus when thymocyte expansion is maximal but decrease dramatically in the adult when steady-state homeostasis is attained. Analysis of mutant mouse strains where thymocyte development is blocked at different stages indicates that lymphostromal interactions ("thymus crosstalk") are required for DL4 down-regulation on cTEC...
December 15, 2008: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/18824585/delta-like-4-is-the-essential-nonredundant-ligand-for-notch1-during-thymic-t-cell-lineage-commitment
#19
COMPARATIVE STUDY
Ute Koch, Emma Fiorini, Rui Benedito, Valerie Besseyrias, Karin Schuster-Gossler, Michel Pierres, Nancy R Manley, Antonio Duarte, H Robson Macdonald, Freddy Radtke
Thymic T cell lineage commitment is dependent on Notch1 (N1) receptor-mediated signaling. Although the physiological ligands that interact with N1 expressed on thymic precursors are currently unknown, in vitro culture systems point to Delta-like 1 (DL1) and DL4 as prime candidates. Using DL1- and DL4-lacZ reporter knock-in mice and novel monoclonal antibodies to DL1 and DL4, we show that DL4 is expressed on thymic epithelial cells (TECs), whereas DL1 is not detected. The function of DL4 was further explored in vivo by generating mice in which DL4 could be specifically inactivated in TECs or in hematopoietic progenitors...
October 27, 2008: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/17628744/a-phase-i-and-pharmacokinetic-study-of-irofulven-and-capecitabine-administered-every-2-weeks-in-patients-with-advanced-solid-tumors
#20
MULTICENTER STUDY
Jérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, Sandrine Faivre, Stephen Shibata, Werner Hilgers, François Goldwasser, François Lokiec, Eric Raymond, Garry Weems, Ajit Shah, John R MacDonald, Esteban Cvitkovic
PURPOSE: To determine the maximum tolerated dose (MTD), recommended dose, dose limiting toxicities (DLT), safety and pharmacokinetics of irofulven combined with capecitabine in advanced solid tumor patients. EXPERIMENTAL DESIGN: Irofulven was given i.v. over 30 min on days 1 and 15 every 4 weeks; capecitabine was given orally twice daily, day 1 to 15. Dose levels (DL) were: irofulven (mg/kg)/capecitabine (mg/m2/day): DL1: 0.3/1,700; DL2: 0.4/1,700; DL3: 0.4/2,000; DL4: 0...
October 2007: Investigational New Drugs
keyword
keyword
110298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"